Home » Newsletters » BioWorld Science

BioWorld Science

March 6, 2012

View Archived Issues

Kythera launches pivotal ATX-101 program

NINA device-coupled RT-LAMP assay allows point-of-care HIV-1 detection

Takeda patents novel antipsychotic drugs

New therapeutics for vascular disease designed in India

Novel antibacterials developed in Israel

ImmunoGen reports new HER3-binding immunotherapies

Bristol-Myers Squibb divulges new products to treat HIV infection

Boston Scientific announces new product launch in Japan

Mitsubishi Tanabe and Daiichi Sankyo enter strategic alliance

FDA accepts NDA resubmitted by Eisai

Phase II AMG-853 trial does not meet primary endpoint

Pre-IND meeting scheduled for influenza drug

Concert Pharmaceuticals enters new collaboation

Canadian study reveals new potential tool for prostate cancer diagnosis

Savient launches named-patient program for gout therapy

Anticancer drugs are possible treatments for lethal Ebola virus infections

Acadia Pharmaceuticals and Allergan extend drug discovery collaboration

Zalicus completes trial of reformulated N-type calcium channel blocker

BioLineRx clear to begin study of BL-7040

FDA issues complete response letter for ezetimibe/atorvastatin tablets

Anthera Pharmaceuticals to continue blisibimod study as planned

MorphoSys completes enrollment in rheumatoid arthritis study

VistaGen partners with Duke University

International phase III trial of MLN-8237 begins

Mayo Clinic receives NIH grant to research use of new peptide to treat heart attacks

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...